Regulation of hormonal therapy resistance by cell cycle machinery

Binoj Chandrasekharan Nair, Ratna K Vadlamudi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Estrogen Receptor (ER) plays a central role in the development and progression of breast cancer. Hormonal therapy substantially improves disease-free survival of ER+ve breast tumors, however acquired resistance to endocrine therapies frequently occur. Emerging data implicate growth factor signaling pathways and their cross talk with ER as major cause of resistance. Both these pathways have been recently shown to use cell cycle machinery as downstream effectors in mediating therapy resistance. Several studies have demonstrated deregulation of cell cycle regulators and their cross talk with ER in therapy resistant tumors. The objective of this article is to review the underlying mechanisms by which tumor cells use cell cycle machinery to override hormonal therapy and to explore cell cycle machinery components as novel therapy targets for overcoming hormonal therapy resistance.

Original languageEnglish (US)
Pages (from-to)395-404
Number of pages10
JournalGene Therapy and Molecular Biology
Volume12
Issue number2
StatePublished - 2008

Fingerprint

Cell Cycle
Estrogen Receptors
Therapeutics
Breast Neoplasms
Disease-Free Survival
Neoplasms
Intercellular Signaling Peptides and Proteins

Keywords

  • Antiestrogens
  • Breast cancer
  • CDKs
  • Cell cycle
  • Co-regulators
  • Estrogen
  • Estrogen receptor
  • Therapy resistance

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Cite this

Regulation of hormonal therapy resistance by cell cycle machinery. / Nair, Binoj Chandrasekharan; Vadlamudi, Ratna K.

In: Gene Therapy and Molecular Biology, Vol. 12, No. 2, 2008, p. 395-404.

Research output: Contribution to journalArticle

@article{1173703b49cb4d0a88cca64cc70cd97a,
title = "Regulation of hormonal therapy resistance by cell cycle machinery",
abstract = "Estrogen Receptor (ER) plays a central role in the development and progression of breast cancer. Hormonal therapy substantially improves disease-free survival of ER+ve breast tumors, however acquired resistance to endocrine therapies frequently occur. Emerging data implicate growth factor signaling pathways and their cross talk with ER as major cause of resistance. Both these pathways have been recently shown to use cell cycle machinery as downstream effectors in mediating therapy resistance. Several studies have demonstrated deregulation of cell cycle regulators and their cross talk with ER in therapy resistant tumors. The objective of this article is to review the underlying mechanisms by which tumor cells use cell cycle machinery to override hormonal therapy and to explore cell cycle machinery components as novel therapy targets for overcoming hormonal therapy resistance.",
keywords = "Antiestrogens, Breast cancer, CDKs, Cell cycle, Co-regulators, Estrogen, Estrogen receptor, Therapy resistance",
author = "Nair, {Binoj Chandrasekharan} and Vadlamudi, {Ratna K}",
year = "2008",
language = "English (US)",
volume = "12",
pages = "395--404",
journal = "Gene Therapy and Molecular Biology",
issn = "1529-9120",
publisher = "Gene Therapy and Molecular Biology",
number = "2",

}

TY - JOUR

T1 - Regulation of hormonal therapy resistance by cell cycle machinery

AU - Nair, Binoj Chandrasekharan

AU - Vadlamudi, Ratna K

PY - 2008

Y1 - 2008

N2 - Estrogen Receptor (ER) plays a central role in the development and progression of breast cancer. Hormonal therapy substantially improves disease-free survival of ER+ve breast tumors, however acquired resistance to endocrine therapies frequently occur. Emerging data implicate growth factor signaling pathways and their cross talk with ER as major cause of resistance. Both these pathways have been recently shown to use cell cycle machinery as downstream effectors in mediating therapy resistance. Several studies have demonstrated deregulation of cell cycle regulators and their cross talk with ER in therapy resistant tumors. The objective of this article is to review the underlying mechanisms by which tumor cells use cell cycle machinery to override hormonal therapy and to explore cell cycle machinery components as novel therapy targets for overcoming hormonal therapy resistance.

AB - Estrogen Receptor (ER) plays a central role in the development and progression of breast cancer. Hormonal therapy substantially improves disease-free survival of ER+ve breast tumors, however acquired resistance to endocrine therapies frequently occur. Emerging data implicate growth factor signaling pathways and their cross talk with ER as major cause of resistance. Both these pathways have been recently shown to use cell cycle machinery as downstream effectors in mediating therapy resistance. Several studies have demonstrated deregulation of cell cycle regulators and their cross talk with ER in therapy resistant tumors. The objective of this article is to review the underlying mechanisms by which tumor cells use cell cycle machinery to override hormonal therapy and to explore cell cycle machinery components as novel therapy targets for overcoming hormonal therapy resistance.

KW - Antiestrogens

KW - Breast cancer

KW - CDKs

KW - Cell cycle

KW - Co-regulators

KW - Estrogen

KW - Estrogen receptor

KW - Therapy resistance

UR - http://www.scopus.com/inward/record.url?scp=77649145385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649145385&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77649145385

VL - 12

SP - 395

EP - 404

JO - Gene Therapy and Molecular Biology

JF - Gene Therapy and Molecular Biology

SN - 1529-9120

IS - 2

ER -